Oscotec Inc.

Translating science into medicine
Sign Up
  1. No Image 27Feb

    Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

  2. No Image 15Sep

    Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

  3. No Image 03Mar

    Other news to note for March 2, 2021

  4. No Image 03Mar

    Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

  5. No Image 01Jun

    Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

  6. No Image 01Jun

    Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

  7. No Image 01Jun

    Yuhan to start phase-3 trial on lung cancer drug Lazertinib

  8. No Image 01Jun

    "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

  9. No Image 01Jun

    AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

  10. No Image 01Jun

    Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

  11. No Image 01Jun

    Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

  12. No Image 01Jun

    Oscotec wins exception policy for continued R&D for new drugs

Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.